Propranolol for the treatment of orbital infantile hemangiomas

Ophthalmic Plast Reconstr Surg. 2011 May-Jun;27(3):190-4. doi: 10.1097/IOP.0b013e318201d344.

Abstract

Purpose: To evaluate the treatment of orbital infantile hemangiomas with systemic (oral) propranolol.

Methods: This study was a retrospective observational case series of 5 infants who were diagnosed with orbital infantile hemangiomas between March and July of 2009.

Results: The average age at presentation was 3.1 months (3 weeks to 9 months). The patients received oral propranolol, with dosage varying among study centers. The patients were treated for an average of 7.1 months. Treatment of 5 infantile hemangioma patients with oral propranolol produced a significant reduction in the size of the hemangioma in 4 (80%) of the patients and a minimal improvement in one patient. No patient had significant adverse events during the treatment period.

Conclusion: Oral propranolol may be an effective treatment for orbital infantile hemangiomas.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adrenergic beta-Antagonists / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Hemangioma, Capillary / drug therapy*
  • Hemangioma, Capillary / pathology
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Orbital Neoplasms / drug therapy*
  • Orbital Neoplasms / pathology
  • Propranolol / therapeutic use*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Antineoplastic Agents
  • Propranolol